First-line treatment, according to the National Comprehensive Cancer Network (NCCN) melanoma guidelines, recommends a combination therapy of BRAFi and MEKi for those with the activating BRAF V600 mutation and metastatic cutaneous melanoma[125]. This evidence concerns the gene BRAF and melanoma.